Characteristics and treatment of AYAs with ongoing chronic disease at last available FU and entering SCROT
| Patient characteristics . | Ongoing chronic disease at last available FU . | Late SCROT (12-36 mo) . | Very late SCROT (36-48 mo) . |
|---|---|---|---|
| Total patients∗ | 265 | 69 | 30 |
| Female (%) | 171 (65) | 45 (65) | 18 (60) |
| Mean age at diagnosis, y (SD) | 14 (2.6) | 14 (2.9) | 14 (2.5) |
| Platelet count ×109/L, median (IQR) | |||
| Initial | 15 (8-31) | 18 (5-47) | 14 (10-37) |
| 6-mo FU | 40 (19-73) | 58 (25-96) | 45 (34-101) |
| 12-mo FU | 46 (23-79) | 64 (36-91) | 41 (28-80) |
| 24-mo FU | 56 (26-93) | 142 (84-215) | 44 (30-85) |
| 36-mo FU | 58 (31-99) | 171 (126-239) | 59 (26-90) |
| 48-mo FU | 62 (32-89) | 180 (144-247) | 162 (130-219) |
| Bleeding, yes (%)† | |||
| Initial | 198/248 (80) | 56/65 (86) | 22/26 (85) |
| 1-6 mo | 164/240 (68) | 38/64 (59) | 16/27 (59) |
| 6-12 mo | 143/229 (62) | 31/62 (50) | 15/25 (60) |
| 12-24 mo | 139/234 (59) | 24/64 (38) | 19/28 (68) |
| 24-36 mo | 103/186 (55) | 11/56 (20) | 18/28 (64) |
| 36-48 mo | 60/129 (47) | 4/33 (12) | 10/27 (37) |
| Drug treatment, n (% of all)† | |||
| Initial, yes | 152/262 (58) | 45/69 (65) | 14/29 (48) |
| Drug (%) | |||
| Corticosteroids | 68 (26) | 23 (33) | 9 (31) |
| IV immunoglobulin and/or anti-D | 108 (41) | 30 (43) | 8 (28) |
| Second or third line | 8 (3) | 1 (1) | - |
| 1-6 mo, yes | 152/258 (59) | 40 /66 (61) | 14/29 (48) |
| Drug (%) | |||
| Corticosteroids | 116 (45) | 30 (45) | 10 (34) |
| IV immunoglobulin and/or anti-D | 92 (36) | 18 (27) | 9 (31) |
| Second or third line | 37 (14) | 12 (18) | 2 (7) |
| 6-12 mo, yes | 130/259 (50) | 29/67 (43) | 15/29 (52) |
| Drug (%) | |||
| Corticosteroids | 71 (27) | 20 (30) | 12 (41) |
| IV immunoglobulin and/or anti-D | 56 (22) | 9 (13) | 4 (14) |
| Second or third line | 51 (20) | 12 (18) | 3 (10) |
| 12-24 mo, yes | 136/257 (53) | 25/68 (37) | 14/29 (48) |
| Drug (%) | |||
| Corticosteroids | 62 (24) | 12 (18) | 10 (34) |
| IV immunoglobulin and/or anti-D | 57 (22) | 13 (19) | 1 (3) |
| Second or third line | 80 (31) | 9 (13) | 6 (21) |
| 24-36 mo, yes | 109/224 (49) | 5/61 (8) | 15/28 (54) |
| Drug (%) | |||
| Corticosteroids | 31 (14) | 3 (5) | 6 (21) |
| IV immunoglobulin and/or anti-D | 44 (20) | 4 (7) | 3 (11) |
| Second or third line | 71 (32) | 0 | 8 (29) |
| 36-48 mo, yes | 82/167 (49) | 0/39 | 2/29 (7) |
| Drug (%) | |||
| Corticosteroids | 30 (18) | 0 | 1 (3) |
| IV immunoglobulin and/or anti-D | 32 (19) | 0 | 2 (7) |
| Second or third line | 54 (32) | 0 | 1 (3) |
| Patient characteristics . | Ongoing chronic disease at last available FU . | Late SCROT (12-36 mo) . | Very late SCROT (36-48 mo) . |
|---|---|---|---|
| Total patients∗ | 265 | 69 | 30 |
| Female (%) | 171 (65) | 45 (65) | 18 (60) |
| Mean age at diagnosis, y (SD) | 14 (2.6) | 14 (2.9) | 14 (2.5) |
| Platelet count ×109/L, median (IQR) | |||
| Initial | 15 (8-31) | 18 (5-47) | 14 (10-37) |
| 6-mo FU | 40 (19-73) | 58 (25-96) | 45 (34-101) |
| 12-mo FU | 46 (23-79) | 64 (36-91) | 41 (28-80) |
| 24-mo FU | 56 (26-93) | 142 (84-215) | 44 (30-85) |
| 36-mo FU | 58 (31-99) | 171 (126-239) | 59 (26-90) |
| 48-mo FU | 62 (32-89) | 180 (144-247) | 162 (130-219) |
| Bleeding, yes (%)† | |||
| Initial | 198/248 (80) | 56/65 (86) | 22/26 (85) |
| 1-6 mo | 164/240 (68) | 38/64 (59) | 16/27 (59) |
| 6-12 mo | 143/229 (62) | 31/62 (50) | 15/25 (60) |
| 12-24 mo | 139/234 (59) | 24/64 (38) | 19/28 (68) |
| 24-36 mo | 103/186 (55) | 11/56 (20) | 18/28 (64) |
| 36-48 mo | 60/129 (47) | 4/33 (12) | 10/27 (37) |
| Drug treatment, n (% of all)† | |||
| Initial, yes | 152/262 (58) | 45/69 (65) | 14/29 (48) |
| Drug (%) | |||
| Corticosteroids | 68 (26) | 23 (33) | 9 (31) |
| IV immunoglobulin and/or anti-D | 108 (41) | 30 (43) | 8 (28) |
| Second or third line | 8 (3) | 1 (1) | - |
| 1-6 mo, yes | 152/258 (59) | 40 /66 (61) | 14/29 (48) |
| Drug (%) | |||
| Corticosteroids | 116 (45) | 30 (45) | 10 (34) |
| IV immunoglobulin and/or anti-D | 92 (36) | 18 (27) | 9 (31) |
| Second or third line | 37 (14) | 12 (18) | 2 (7) |
| 6-12 mo, yes | 130/259 (50) | 29/67 (43) | 15/29 (52) |
| Drug (%) | |||
| Corticosteroids | 71 (27) | 20 (30) | 12 (41) |
| IV immunoglobulin and/or anti-D | 56 (22) | 9 (13) | 4 (14) |
| Second or third line | 51 (20) | 12 (18) | 3 (10) |
| 12-24 mo, yes | 136/257 (53) | 25/68 (37) | 14/29 (48) |
| Drug (%) | |||
| Corticosteroids | 62 (24) | 12 (18) | 10 (34) |
| IV immunoglobulin and/or anti-D | 57 (22) | 13 (19) | 1 (3) |
| Second or third line | 80 (31) | 9 (13) | 6 (21) |
| 24-36 mo, yes | 109/224 (49) | 5/61 (8) | 15/28 (54) |
| Drug (%) | |||
| Corticosteroids | 31 (14) | 3 (5) | 6 (21) |
| IV immunoglobulin and/or anti-D | 44 (20) | 4 (7) | 3 (11) |
| Second or third line | 71 (32) | 0 | 8 (29) |
| 36-48 mo, yes | 82/167 (49) | 0/39 | 2/29 (7) |
| Drug (%) | |||
| Corticosteroids | 30 (18) | 0 | 1 (3) |
| IV immunoglobulin and/or anti-D | 32 (19) | 0 | 2 (7) |
| Second or third line | 54 (32) | 0 | 1 (3) |
A total of 364 patients were analyzed here. For the remaining 63 patients no classification was possible (relevant information missing.)
Percentage of patients with complete information regarding the analyzed parameter at the defined time point. The total number of patients used as denominator may differ to the patient count reported at the top of the column.